Product Description
Mechanisms of Action: CYP17 Inhibitor,AR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocrin
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Small Cell Sarcoma|Breast Cancer|Melanoma|Small Cell Carcinoma|Prostate Cancer|Glioblastoma|Basal Cell Carcinoma|Head and Neck Cancer|Neck Pain|Thyroid Cancer|Renal Cell Carcinoma|Bladder Cancer|Salivary Gland Cancer|Anal Gland Cancer|Low Back Pain|Goodpasture Syndrome|Triple Negative Breast Cancer|Male Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 4CAST | P2 |
Recruiting |
Triple Negative Breast Cancer |
2024-07-01 |
|
| START | P2 |
Terminated |
Basal Cell Carcinoma|Renal Cell Carcinoma|Glioblastoma|Low Back Pain|Goodpasture Syndrome|Anal Gland Cancer|Small Cell Sarcoma|Breast Cancer|Bladder Cancer|Salivary Gland Cancer|Neck Pain|Prostate Cancer|Head and Neck Cancer|Melanoma|Small Cell Carcinoma|Thyroid Cancer |
2021-02-28 |
|
| 2011-004103-20 | P2 |
Completed |
Prostate Cancer |
2019-01-23 |
|
| CLARITY-01 | P2 |
Completed |
Triple Negative Breast Cancer|Male Breast Cancer |
2019-01-01 |
51% |